Novo Nordisk advances amycretin to late-stage trial after positive diabetes weight-loss results

Novo Nordisk’s experimental drug amycretin shows strong results in its mid-stage trial, helping type 2 diabetes patients lose up to 14.5% of their body weight.

Here's Why Novo Nordisk Stock Popped Today

Yesterday's "bad" news from Novo Nordisk came from its Phase 3 trials of oral semaglutide in the early stage of Alzheimer's ...

Novo’s next-gen obesity drug shows positive results, heads to late-stage testing

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to ...

Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

What's Happening With Novo Nordisk Stock?

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.

Novo Nordisk (NVO) is Trending On Reddit – Here’s Why

We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Novo Nordisk A/S (NYSE:NVO) ...

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...

Novo Nordisk Stock Share Price Today: Why company's shares are down? Here's Alzheimer drug’s trial outcome, stock market impact, analysts insights

Novo Nordisk stock share price today fell after the company announced that semaglutide, used in Ozempic and Wegovy, failed to ...